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Orphanet compiles 6500 research projects. This informa-
tion been analysed to identify areas in need of collabora-
tive research projects and to target future calls for
proposals. The analysis of the distribution of number of
diseases by number of treatments in development showed
that most RD have no more than 3 orphan designations,
whereas 53 RD have over three orphan designations. Simi-
lar results were obtained when clinical trials, marketed
drugs, patient registries and preclinical/epidemiological/
basic research were analysed. Some of the diseases which
were over-represented upstream in the process of R&D
(with a treatment on the market or drugs in development)
are also well represented regarding ongoing research, like
Cystic fibrosis, pulmonary arterial hypertension and some
rare cancers. Diseases with a higher prevalence are antici-
pated to have more treatments in development: this
assumption is not backed up by our data analysis. The
best represented medical domain in terms of percentage
of diseases with MA/OD is rare tumours, followed by
Systemic and Rheumatologic diseases, Respiratory
diseases, Immunological diseases, Metabolic diseases and
Haematological diseases. It seems that the most mature
fields keep on investing in research and are also the stron-
gest ones regarding the products in development, and
even in basic research for some of them. Other fields,
however, like Neurology, seem to be essentially in develop-
ment, since the percentage of diseases with MA is low
compared to other domains and to the percentage of neu-
rologic diseases with OD, clinical trials and research. The
absence of orphan designations for some medical domains,
like Cardiology, could be explained by the fact that the
Cardiology rare diseases benefit from treatments already
available for these diseases’ common forms. This work
was supported by the RareDiseasePlatform contract
(RDPlatform), a three-year project which began in May
2008, financed by the European Union’s Seventh Frame-
work Programme (HEALTH-F2-2008-2012).
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